JP2017536114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536114A5 JP2017536114A5 JP2017524014A JP2017524014A JP2017536114A5 JP 2017536114 A5 JP2017536114 A5 JP 2017536114A5 JP 2017524014 A JP2017524014 A JP 2017524014A JP 2017524014 A JP2017524014 A JP 2017524014A JP 2017536114 A5 JP2017536114 A5 JP 2017536114A5
- Authority
- JP
- Japan
- Prior art keywords
- vnar
- amino acid
- encode
- domain
- codons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 16
- 235000001014 amino acid Nutrition 0.000 claims 15
- 238000000034 method Methods 0.000 claims 11
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 108020004705 Codon Proteins 0.000 claims 7
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 238000003498 protein array Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14003700.3 | 2014-11-03 | ||
| EP14003700 | 2014-11-03 | ||
| PCT/EP2015/002086 WO2016070959A1 (en) | 2014-11-03 | 2015-10-21 | Methods for generating bispecific shark variable antibody domains and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536114A JP2017536114A (ja) | 2017-12-07 |
| JP2017536114A5 true JP2017536114A5 (enExample) | 2018-11-29 |
| JP6734271B2 JP6734271B2 (ja) | 2020-08-05 |
Family
ID=51945671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524014A Expired - Fee Related JP6734271B2 (ja) | 2014-11-03 | 2015-10-21 | 二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11001640B2 (enExample) |
| EP (1) | EP3215531A1 (enExample) |
| JP (1) | JP6734271B2 (enExample) |
| CN (1) | CN107074961A (enExample) |
| AU (1) | AU2015342264B2 (enExample) |
| CA (1) | CA2966397A1 (enExample) |
| IL (1) | IL252008A0 (enExample) |
| WO (1) | WO2016070959A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3033082A1 (en) * | 2016-08-06 | 2018-02-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| KR20210029298A (ko) * | 2017-08-16 | 2021-03-15 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질 |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| US12351642B2 (en) | 2018-09-14 | 2025-07-08 | Ossianix, Inc. | TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| CN112301431B (zh) * | 2020-08-12 | 2023-01-31 | 华东理工大学 | 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN112940120B (zh) * | 2021-05-14 | 2021-08-17 | 深圳海创生物技术有限公司 | 降钙素原单域抗体及其应用和试剂盒 |
| WO2023077287A1 (en) * | 2021-11-03 | 2023-05-11 | City university of hong kong shenzhen research institute | High-affinity anti-egfp and anti-sars-cov-2 vnar single domain antibodies and use thereof |
| CN115975010B (zh) * | 2022-08-31 | 2026-03-24 | 闽江学院 | 一种十足目虹彩病毒1的单域抗体及其制备方法和应用 |
| CN116143913B (zh) * | 2022-12-30 | 2026-03-27 | 闽江学院 | 一种结合SARS-CoV-2 RBD的鲨鱼源单域抗体及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL403488A1 (pl) | 2001-05-24 | 2013-07-08 | Zymogenetics, Inc. | Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina |
| PH12012501744A1 (en) * | 2010-03-03 | 2021-08-09 | Boehringer Ingelheim Int | Biparatopic abeta binding polypeptides |
| WO2012023053A2 (en) * | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| WO2013167883A1 (en) | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
| JP6616284B2 (ja) * | 2013-04-23 | 2019-12-04 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン | 特異的結合分子の人工ライブラリー |
-
2015
- 2015-10-21 CN CN201580059697.2A patent/CN107074961A/zh active Pending
- 2015-10-21 WO PCT/EP2015/002086 patent/WO2016070959A1/en not_active Ceased
- 2015-10-21 AU AU2015342264A patent/AU2015342264B2/en not_active Ceased
- 2015-10-21 CA CA2966397A patent/CA2966397A1/en not_active Abandoned
- 2015-10-21 JP JP2017524014A patent/JP6734271B2/ja not_active Expired - Fee Related
- 2015-10-21 EP EP15785053.8A patent/EP3215531A1/en not_active Withdrawn
- 2015-10-21 US US15/523,888 patent/US11001640B2/en not_active Expired - Fee Related
-
2017
- 2017-04-27 IL IL252008A patent/IL252008A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017114866A5 (enExample) | ||
| IL275270A (en) | Recombinant scavenger cell surface proteins | |
| HRP20201634T1 (hr) | Monoklonsko protutijelo protiv interleukina-31 | |
| JP2016029056A5 (enExample) | ||
| JP2016026303A5 (enExample) | ||
| HRP20250850T1 (hr) | Antitijela protiv claudina 18.2 korisna u dijagnozi raka | |
| AR108066A1 (es) | Receptores quiméricos para cll-1 y métodos de uso de los mismos | |
| IL273196B1 (en) | Claudin 6 antibodies and methods of cancer treatment | |
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| JP2019500862A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2018121657A5 (enExample) | ||
| RU2018137419A (ru) | Связывающиеся с cd38 и pd-l1 молекулы | |
| JP2015529826A5 (enExample) | ||
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| JP2013535191A5 (enExample) | ||
| FI3227342T4 (fi) | Proteiininen heterodimeeri ja sen käyttö | |
| JP2014158485A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2018528786A5 (enExample) | ||
| JP2016502843A5 (enExample) | ||
| Hudson et al. | Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes | |
| JP2013509878A5 (enExample) | ||
| JP2017522886A5 (enExample) | ||
| RU2019129917A (ru) | Химерный антигенный рецептор |